Vildagliptin
| 證據等級: L5 | 預測適應症: 10 個 |
目錄
Vildagliptin: From Type 2 Diabetes Mellitus to Classic Stiff Person Syndrome
One-Sentence Summary
Vildagliptin is a DPP-4 (dipeptidyl peptidase-IV) inhibitor originally developed for glycemic control in type 2 diabetes mellitus. The TxGNN model predicts it may be effective for Classic Stiff Person Syndrome, but this prediction is currently supported by 0 clinical trials and 0 publications — it is a model-only signal.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Type 2 Diabetes Mellitus (drug class/literature-derived; no Norway license record exists for this drug) |
| Predicted New Indication | Classic Stiff Person Syndrome |
| TxGNN Prediction Score | 99.88% |
| Evidence Level | L5 |
| Norway Market Status | ✗ Not Marketed |
| Number of Authorizations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available (DG002, High severity). Based on literature retrieved for this evidence pack, vildagliptin is a selective DPP-4 inhibitor that blocks degradation of the incretin hormones GLP-1 and GIP, thereby enhancing glucose-dependent insulin secretion and suppressing inappropriate glucagon release — its efficacy in type 2 diabetes is well documented.
For the top-ranked prediction, classic stiff person syndrome, there is no known mechanistic link to the DPP-4/incretin pathway. Stiff person syndrome is an anti-GAD65 autoimmune neurological disorder affecting GABAergic inhibitory transmission, a biological system unrelated to incretin signaling. The evidence pack itself notes this explicitly: the prediction rests solely on the TxGNN embedding score, with no supporting trials or publications identified.
By contrast, other candidates further down the model's ranked list have stronger biological plausibility — notably type 1 diabetes mellitus (rank 10), where DPP-4 inhibition could theoretically prolong endogenous GLP-1 activity to support residual β-cell function, and this is backed by an actual randomized controlled trial (see Conclusion). This top prediction should therefore be read as a low-confidence, mechanism-agnostic model output rather than a biologically grounded hypothesis.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
Norway Market Information
Vildagliptin currently holds no marketing authorization in Norway (market status: Not Marketed; 0 licenses on record). No product-level dosage form or approved-indication data is available for this market.
Safety Considerations
Please refer to the package insert for safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: The top-ranked predicted indication (classic stiff person syndrome) has no mechanistic rationale, no clinical trial evidence, and no supporting literature — it is a pure L5 model prediction. Combined with the lack of Norway market authorization and missing safety/MOA data, there is no basis to advance this candidate.
To proceed, the following is needed:
- Official product label / regulatory safety data (warnings, contraindications) — currently blocking (DG001)
- Verified mechanism of action data from DrugBank or equivalent source (DG002)
- Independent mechanistic or preclinical rationale connecting DPP-4 inhibition to GAD65-mediated autoimmune neurological disease before any further evaluation
- Alternative candidate worth tracking instead: type 1 diabetes mellitus (rank 10) already has an L2/S2 "Research Question" status, including a completed double-blind RCT (rapamycin + vildagliptin, PMID 33124663) targeting β-cell function recovery — this is a substantially stronger repurposing signal than the top-ranked prediction and may warrant separate evaluation
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.